No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.
BACKGROUND
In a retrospective study of HIV-infected patients, we investigated the influence of the MDR1 genotype (G2677T/A and C3435T) on the virological and immunological response of treatment naive patients.


METHODS
The MDR1 genotype was analysed from 72 patients in whom antiretroviral therapy was initiated between 1998 and 2004. Data were obtained at week 4, 12, 24 and 48 and were analysed by the Kruskal-Wallis test.


RESULTS
During the first 48 weeks of antiretroviral therapy, there were no significant differences in the virological and immunological response with respect to the MDR1 2677 and 3435 genotypes and the 2677/3435 haplotype.


CONCLUSIONS
In view of different results from several studies concerning the influence of MDR1 polymorphisms on the immunological and virological response to antiretroviral therapy, further studies with larger patient groups and longer follow-up are necessary in order to resolve conflicting issues.
Winzer
Ralf
R
Medical Policlinic, Division of Infectious Diseases, University of Würzburg, Josef-Schneider-Str, 2, 97080 Würzburg, Germany. Winzer_R@klinik.uni-wuerzburg.de
Langmann
Peter
P
Zilly
Michael
M
Tollmann
Franz
F
Schubert
Jörg
J
Klinker
Hartwig
H
Weissbrich
Benedikt
B
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D005260:Female; D019450:Genes, MDR; D005838:Genotype; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D019562:Viral Load
D019380:Anti-HIV Agents